Compare FCBC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FCBC | SGMT |
|---|---|---|
| Founded | 1874 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.3M | 761.6M |
| IPO Year | 1996 | 2021 |
| Metric | FCBC | SGMT |
|---|---|---|
| Price | $47.58 | $9.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $27.91 |
| AVG Volume (30 Days) | 112.1K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-16-2026 |
| Dividend Yield | ★ 4.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $24.39 | N/A |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.21 | $4.50 |
| 52 Week High | $50.17 | $11.45 |
| Indicator | FCBC | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 53.33 |
| Support Level | $46.31 | $8.54 |
| Resistance Level | $49.64 | $11.33 |
| Average True Range (ATR) | 1.42 | 0.62 |
| MACD | -0.19 | 0.11 |
| Stochastic Oscillator | 18.51 | 71.30 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.